Best of ASCO 2024, Albuquerque

Albuquerque, NM US
June 22, 2024 to June 23, 2024

This CME-accredited oncology conference, Best of ASCO 2024, Albuquerque, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.

Expert faculty will provide a comprehensive overview of practice-changing abstracts presented at the 2024 ASCO® Annual Meeting (ASCO2024) in June 2024. The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in the field. Expert faculty will place abstract findings from ASCO2024 into clinical contexts and discuss how the results may change the current standard of care. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Oncology residents/fellows
  • Oncology NPs/PAs
  • Oncology pharmacists
  • Oncology nurses

Organizing Committee: 

Course Director:

Binay Shah, MD, MHA - Binaytara Foundation

Conference Chair:

Ursa Brown-Glaberman, MD - University of New Mexico 

VENUE INFORMATION

Rooms have been set aside on June 21-23, 2024, at the rate of $189.00 plus taxes per night (Single Occupancy).

Below is a link for online bookings. The link may be used over the actual room block dates only, and the date of arrival and departure should be selected. Individuals may also contact our reservations team to book via phone at (505) 843-6300.

(Booking Link):  BEST OF ASCO

(Call-In Code): BEST OF ASCO

Please note the Reservation Cut-Off and Rooming List Due Date will be: May 22nd, 2024.

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Discuss new and updated treatment options for patients with hematologic malignancies and solid tumors
  2. Identify side effects, indications, and contra-indications of therapies used to diagnose and treat cancers
  3. Explain how to effectively manage side-effects associated with cancer treatment
  4. Review abstracts presented at ASCO® 2024 and discuss their application in clinical settings

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 10.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.50 Contact Hours.
Course opens: 
11/07/2023
Course expires: 
09/06/2024
Event starts: 
06/22/2024 - 8:00am PDT
Event ends: 
06/23/2024 - 4:00pm PDT
Cost:
$350.00

DAY 1 - June 22nd, 2024


All times below are listed in Mountain Standard Time (MST).

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:25 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA


08:25 AM – 09:55 AM  Session 1 - Hematologic Malignancies

Session Chair: Ethan Binder, MD

08:25 AM 08:55 AM  MDS/Leukemias -  Charles Foucar, MD

08:55 AM  09:25 AM  Multiple Myeloma - Shashank Cingam, MD

09:25 AM  09:55 AM  Lymphoma & CLL Updates - Parameswaran Venugopal, MD


09:55 AM – 10:25 AM  Break & Exhibits


10:25 AM – 11:55 AM  Session 2 - Thoracic Oncology

Session Chair: Fei Gu, MD, PhD

10:25 AM  10:55 AM  Early-Stage Lung Cancer - Moises Harari-Turquie, MD

10:55 AM  11:25 AM  Metastatic Lung Cancer - Atul Kumar, MD, PhD

11:25 AM – 11:55 AM  Small Cell Lung Cancer - Eric K. Singhi, MD


11:55 AM – 12:55 PM  Lunch & Exhibits

12:10 PM to 12:55 PM

Product Theater Sponsored by Merck in Alvarado H

A Treatment Option for Adult Patients With Locally Advanced or Metastatic Urothelial Cancer – by Putao Cen, M.D.

This is a non-CME activity


12:55 PM – 01:25 PM  Session 3 - Case-Based Theranostics Updates

Session Chair: Gregg Franklin, MD, PhD

12:55 PM  01:05 PM   Introduction to Theranostics  - Hossein Mehdikhani, MD

01:05 PM  01:15 PM  Case 1 - Neda Hashemi, MD

01:15 PM  01:25 PM  Case 2 - Bernard Tawfik, MD


01:25 PM – 03:05 PM  Session 4 - General Oncology

Session Chair: Sardar Zakariya Imam, MD

01:25 PM  01:50 PM  Melanoma - Michael K Wong, MD, PhD, FRCPC

01:50 PM  02:15 PM  Head and Neck Cancer - David Lee, MD, PhD

02:15 PM  02:40 PM  Gynecologic Cancer - Thanh Dellinger, MD

02:40 PM  03:05 PM  Supportive Care in Solid Tumors - Ala Ebaid, MD


03:05 PM – 03:35 PM  Break & Exhibits


03:35 PM – 05:05 PM  Session 5 - Genitourinary Cancer

Session Chair: William Adler, MD

03:35 PM – 04:05 PM  Prostate Cancer - Jude Khatib, MD

04:05 PM  04:35 PM  Bladder Cancer - Neda Hashemi, MD

04:35 PM – 05:05 PM  Kidney Cancer - Arpita Desai, MD


 

DAY 2 - June 23rd, 2024
 

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 09:00 AM  Session 6 - Case-Based Presentations 2

Session Chair: Malcolm Purdy, MD

08:00 AM  08:15 AM  Case 1: Thoracic Oncology - Tripti Chopade, MD, MBBS

08:15 AM  08:30 AM  Case 2: GU Cancer - Mahmoud Abdelsamia, MD

08:30 AM – 08:45 AM  Case 3: GI Cancer - Amir Sohail, MD

08:45 AM  09:00 AM  Case 4: Breast Cancer - Nicole Hill, MD


09:00 AM – 10:30 AM  Session 7 - GI Cancer

Session Chair: Andrea Teague, MD

09:00 AM – 09:30 AM  Colorectal Cancer: Management of Colorectal Liver Metastasis - Matthew Hernandez, MD

09:30 AM  10:00 AM  Hepatobiliary and Pancreatic Malignancies - Erika Maestas, MD

10:00 AM  10:30 AM  Peritoneal Surface Disease - Alissa Greenbaum, MD


10:30 AM – 10:45 AM  Break & Exhibits


10:45 AM – 12:15 PM  Session 8 - Breast Cancer

Session Chair: Calvin Ridgeway, MD

10:45 AM  11:15 AM  Early-Stage Breast Cancer - Jacklyn Nemunaitis, MD

11:15 AM  11:45 AM  Metastatic Breast Cancer 1 (hormone receptor-positive) - Katherine Sanchez, MD

11:45 AM – 12:15 PM  Metastatic Breast Cancer 2 (HER2 +ve and triple-negative breast cancer) - Ursa Brown-Glaberman, MD


12:15 PM  Adjourn

Hotel Albuquerque at Old Town
800 Rio Grande Blvd NW
Albuquerque, NM 87104
United States

Rooms have been set aside on June 21-23, 2024, at the rate of $189.00 plus taxes per night (Single Occupancy).

Below is a link for online bookings. The link may be used over the actual room block dates only, and the date of arrival and departure should be selected. Individuals may also contact our reservations team to book via phone at (505) 843-6300.

(Booking Link):  BEST OF ASCO

(Call-In Code): BEST OF ASCO

Please note the Reservation Cut-Off and Rooming List Due Date will be: May 22nd, 2024.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Ursa Brown-Glaberman, Associate Professor

has a financial relationship (Independent contractor) with SeaGen;.
Session Chair(s)

will adler, MD

has no relevant financial relationships to disclose at this time.

Ethan Binder, MD

has no relevant financial relationships to disclose at this time.

Gregg Franklin, MD, PhD

has a financial relationship (Other) with BAYER;.

Fei Gu, MD PhD

has no relevant financial relationships to disclose at this time.

Sardar Imam, MBBS

has a financial relationship (Other) with Pharmacyclics;.
has a financial relationship (Other) with AbbVie;.
has a financial relationship (Other) with Boston Biomedical;.
has a financial relationship (Other) with QED Therapeutics;.
has a financial relationship (Other) with Pfizer;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Astra Zenica;.
has a financial relationship (Other) with SeaGen;.
has a financial relationship (Other) with Exelixis;.
has a financial relationship (Other) with Janssen Pharmaceuticals;.
has a financial relationship (Other) with Cardinal Health;.

Malcolm Purdy

has no relevant financial relationships to disclose at this time.

Calvin Ridgeway, MD

has a financial relationship (Other) with Castle Bio Sciences;.

Andrea Teague, Board Certified in Hematology and Oncology

has a financial relationship (Gift) with Curio Science;.
Speaker/Topic Presenter(s)

Shashank Cingam

has no relevant financial relationships to disclose at this time.

Thanh Dellinger, MD

has a financial relationship (Other) with Reger, Inc;.

Arpita Desai, MD

has a financial relationship (Other) with Aveo;.
has a financial relationship (Other) with Exelixis;.
has a financial relationship (Other) with Merck;.
has a financial relationship (Other) with Janssen;.

Ala Ebaid, MD

has a financial relationship (Other) with Sobi;.

Charles Foucar, MD

has no relevant financial relationships to disclose at this time.

Alissa Greenbaum

has no relevant financial relationships to disclose at this time.

Moises Harari Turquie, MD

has no relevant financial relationships to disclose at this time.

Neda Hashemi

has a financial relationship (Other) with Eisai;.

Matthew Hernandez, MD

has no relevant financial relationships to disclose at this time.

Jude Khatib, MD

has no relevant financial relationships to disclose at this time.

Atul Kumar

has no relevant financial relationships to disclose at this time.

David Lee, MD, PhD

has no relevant financial relationships to disclose at this time.

Erika Maestas, Medical Oncology

has no relevant financial relationships to disclose at this time.

Jackie Nemunaitis, MD

has no relevant financial relationships to disclose at this time.

Katherine Sanchez, MD

has no relevant financial relationships to disclose at this time.

Eric Singhi, Eric K. Singhi, MD

has no relevant financial relationships to disclose at this time.

Parameswaran Venugopal, MD

has a financial relationship (Professional Services) with BeiGene;.

Michael Wong

has a financial relationship (Professional Services) with Castle Biosciences;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with Sun Pharma;.
has a financial relationship (Professional Services) with Incyte;.
has a financial relationship (Professional Services) with Replimune;.
Case Presenter(s)

Mahmoud Abdelsamia, MD

has no relevant financial relationships to disclose at this time.

Tripti Chopade, MBBS, MD

has no relevant financial relationships to disclose at this time.

Neda Hashemi

has a financial relationship (Other) with Eisai;.

Nicole Hill, MD FACS

has no relevant financial relationships to disclose at this time.

Hossein Mehdikhani, MD

has no relevant financial relationships to disclose at this time.

Amir Sohail, MD

has no relevant financial relationships to disclose at this time.

Bernard Tawfik, MD

has no relevant financial relationships to disclose at this time.

Available Credit

  • 10.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.